Scarica l'app Stockscreener
1.31
9.03%
-0.13
Dopo l'orario di chiusura:
1.25
-0.06
-4.58%
Precedente Chiudi:
$1.44
Aprire:
$1.45
Volume 24 ore:
409.66K
Relative Volume:
1.83
Capitalizzazione di mercato:
$59.56M
Reddito:
-
Utile/perdita netta:
$-81.22M
Rapporto P/E:
-0.4267
EPS:
-3.07
Flusso di cassa netto:
$-74.41M
1 W Prestazione:
+32.32%
1M Prestazione:
+67.95%
6M Prestazione:
+11.02%
1 anno Prestazione:
-45.42%
Intervallo 1D:
$1.25
$1.45
Intervallo di 1 settimana:
$1.035
$1.54
Portata 52W:
$0.49
$2.593
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St
Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com
XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com
XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com
XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily
Market Resilience: XTI Aerospace Inc. (XTIA) Finishes Weak at 0.22, Down -4.06 - The Dwinnex
Tencent-Backed AI Drug Researcher Xtalpi’s Shares Double On Revenue Rise - Forbes Africa
Xilio Therapeutics Inc (XLO)’s highs and lows: A closer look at its stock price fluctuations - US Post News
(XFLT) Trading Signals - Stock Traders Daily
Balance Sheet Breakdown: Xilio Therapeutics Inc (XLO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
There’s evidence fragile X symptoms can be reduced with an experimental drug - KUOW News and Information
Slew of New Drugs Sends Xencor Shares Soaring - Los Angeles Business Journal
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XTX Topco Ltd Has $2.01 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
XLO Stock Sees Decline of Approximately -10.26% in Last Five Days - Knox Daily
Analytical Lens: Exploring Xilio Therapeutics Inc (XLO)’s Financial Story Through Ratios - The Dwinnex
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire
Xilio Therapeutics shares hold Buy rating on clinical trial focus - Investing.com
Xilio Therapeutics shares hold Buy rating on clinical trial focus By Investing.com - Investing.com Canada
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - GlobeNewswire
Understanding the Risks of Investing in Xilio Therapeutics Inc (XLO) - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Simply Wall St
Head to Head Analysis: Indivior (NASDAQ:INDV) versus Xilio Therapeutics (NASDAQ:XLO) - Defense World
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth? - Yahoo Finance
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Drops By 83.1% - Defense World
$82 million series A round propels Exsilio into gene editing race - The Pharma Letter
Head to Head Analysis: Xilio Therapeutics (NASDAQ:XLO) versus VBI Vaccines (NASDAQ:VBIV) - Defense World
Biopharma Layoff Tracker 2024: Ginkgo, Cara, Barinthus and More Cut Staff - BioSpace
Xilio Therapeutics Inc (XLO) stock analysis: A comprehensive overview – US Post News - US Post News
Investing in Xilio Therapeutics Inc (XLO): What You Must Know – Knox Daily - Knox Daily
Xilio Therapeutics Inc (XLO)'s Market Momentum: Closing Strong at 0.95, Down -0.33 – DWinneX - The Dwinnex
Xilio Therapeutics, Inc. (NASDAQ:XLO) Shares Sold by Octagon Capital Advisors LP - Defense World
Xilio Therapeutics expands board with industry experts - Investing.com India
Xilio Therapeutics expands board with industry experts By Investing.com - Investing.com
Xilio Therapeutics Enhances Board with Two New DirectorsTipRanks.com - TipRanks
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - ForexTV.com
Was there any good news for Xilio Therapeutics Inc (XLO) stock in the last session? – US Post News - US Post News
Monitoring Xilio Therapeutics Inc (XLO) after recent insider movements – Knox Daily - Knox Daily
Xilio Therapeutics (NASDAQ:XLO) Trading Down 2.8% - Defense World
Xilio Therapeutics Inc (XLO) Stock: A Year of Decreases and Increases - The InvestChronicle
Gilead and Cartography enter deal to develop cancer therapies - Yahoo Finance
Market Recap: Xilio Therapeutics Inc (XLO)'s Negative Momentum, Closing at 1.05 – DWinneX - The Dwinnex
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):